Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual Multiple Myeloma Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological Reoptimizing Standards and Redefining Approaches

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches

541
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Leire Burgos, Luis Esteban Tamariz-Amador, Noemí Puig, et al. 

See abstract for more info.

 

542
Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study

Thorir Einarsson Long, Olafur Skuli Indridason, Runolfur Palsson, et al. 

See abstract for more info.

 

543
Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis

Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, et al. 

See abstract for more info.

 

544
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Noemi Puig, Teresa Contreras Sanfeliciano, Bruno Paiva, et al. 

See abstract for more info.

 

545
Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur,  Mariateresa Fulciniti, Sanika Derebail, et al. 

See abstract for more info.

 

546
Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, et al. 

See abstract for more info.